TAF6L: A Potential Drug Target and Biomarker for PCAF-Associated Factor 65-Alpha

Target Name: TAF6L

NCBI ID: G10629

TAF6L

Other Name(s): PCAF-associated factor 65-alpha | PCAF-associated factor 65 alpha | PAF65A | PAF65-alpha | TAF6-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 6L | TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65kDa | p300/CBP-associated factor (PCAF)-associated factor 65 | TATA-box binding protein associated factor 6 like | TAF6L_HUMAN

TAF6L: A Potential Drug Target and Biomarker for PCAF-Associated Factor 65-Alpha

Abstract:

PCAF-associated factor 65-alpha (TAF6L) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases. This protein plays a crucial role in the regulation of cell growth, apoptosis, and angiogenesis, and its dysfunction has been implicated in the development and progression of numerous diseases. In this article, we will discuss the molecular mechanisms of TAF6L, its potential drug targets, and its potential as a biomarker for various diseases.

Introduction:

PCAF-associated factor 65-alpha (TAF6L) is a non-coding RNA molecule that is expressed in various tissues and cells throughout the body. It has been shown to play a critical role in the regulation of cell growth, apoptosis, and angiogenesis, and its dysfunction has been implicated in the development and progression of numerous diseases. TAF6L is a member of the PCAF family, which includes several other non-coding RNAs that play important roles in the regulation of cell growth and differentiation.

Molecular Mechanisms of TAF6L:

The molecular mechanisms of TAF6L are not well understood, but it is known to play a role in the regulation of cell growth and apoptosis. TAF6L has been shown to induce the growth inhibition pathway in various cell types, including cancer cells, and to play a role in the regulation of cell apoptosis. Additionally, TAF6L has been shown to regulate the expression of several genes that are involved in cell growth, apoptosis, and angiogenesis.

Potential Drug Targets:

TAF6L has been identified as a potential drug target for various diseases, including cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases. Its role in these diseases is not well understood, but it is known to play a critical role in their development and progression. For example, TAF6L has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. It is also involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential drug targets, TAF6L has also been shown to be a potential biomarker for various diseases. Its dysfunction has been implicated in the development and progression of cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases. Additionally, TAF6L has been shown to be involved in the regulation of cancer cell growth and has been used as a potential biomarker for cancer.

Conclusion:

TAF6L is a non-coding RNA molecule that has been shown to play a critical role in the regulation of cell growth, apoptosis, and angiogenesis. Its dysfunction has been implicated in the development and progression of numerous diseases, including cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases. TAF6L is also a potential drug target and biomarker for various diseases, and further research is needed to fully understand its role in these conditions.

Protein Name: TATA-box Binding Protein Associated Factor 6 Like

Functions: Functions as a component of the PCAF complex. The PCAF complex is capable of efficiently acetylating histones in a nucleosomal context. The PCAF complex could be considered as the human version of the yeast SAGA complex (Probable). With TAF5L, acts as an epigenetic regulator essential for somatic reprogramming. Regulates target genes through H3K9ac deposition and MYC recruitment which trigger MYC regulatory network to orchestrate gene expression programs to control embryonic stem cell state. Functions with MYC to activate target gene expression through RNA polymerase II pause release (By similarity)

The "TAF6L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF6L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets